Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 12, 2022ACS Applied Materials & Interfaces

Intelligent Biomimetic Nanoplatform for Systemic Treatment of Metastatic Triple-Negative Breast Cancer via Enhanced EGFR-Targeted Therapy and Immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXiaoxi WangKunming UniversityXZXueqin ZhuSun Yat-sen UniversityBLBingyu LiCapital Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2022) studied this question.

synapsesocial.com/papers/6a7c95bfcc6f1443deba5c4dhttps://doi.org/10.1021/acsami.2c02925
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC2017 · 83 citations
  2. 2Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study2018 · 645 citations
  3. 3From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)2018 · 1,312 citations